Assistant Scientist, Hospital for Special Surgery
Assistant Professor, Department of Microbiology and Immunology, Weill Medical College of Cornell University
Member, Graduate Program in Immunology and Microbial Pathogenesis, Weill-Cornell
Member, Allied Graduate Program in Biochemistry, Cell and Molecular Biology (BCMB), Weill-Cornell
Rogatsky I., Zarember K.A. and Yamamoto K.R. (2001) Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J. 20:6071-83.
Rogatsky I., Luecke H.F., Leitman D.C. and Yamamoto K.R. (2002) Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc. Natl. Acad. Sci. USA, 99:16701-6.
Rogatsky I., Wang J.-C., Derynck M.K., Nonaka D.F., Khodabakhsh D.B., Haqq C.M., Darimont B.D., Garabedian M.J. and Yamamoto K.R. (2003) Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA, 100:13845-50.
Chen W., Rogatsky I. and Garabedian M.J. (2006) MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol. Endocrinol. 20:560-72.
Reily M.M., Pantoja C., Hu X., Chinenov Y. and Rogatsky I. (2006) The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J. 25:108-17.
Takayama S., Rogatsky I., Schwarcz L.E., Darimont B.D. (2006) The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-#-Catenin complex. J. Biol. Chem. 281:17856-63.
Rogatsky I. and Ivashkiv L.B. (2006) Glucocorticoid modulation of cytokine signalling. Tissue Antigens, 68:1-12.
Chinenov Y. and Rogatsky I. (2007) Glucocorticoids and the innate immune system: Crosstalk with the Toll-like receptor signaling network. Mol. Cell. Endocrinol. 275:30-42.
Chen W., Dang T., Blind R., Wang Z., Cavasotto N.C., Hittelman A., Rogatsky I., Logan S.K. and Garabedian M.J. (2008) Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol. Endocrinol. 22:1754-66.
Chinenov Y., Sacta M.A., Cruz A.R., Rogatsky I. (2008) GRIP1-associated SET-domain methyltransferase in glucocorticoid receptor target gene expression. Proc. Natl. Acad. Sci. USA 105: 20185-90.
For more publications, please see the PubMed listing.Glucocorticoid hormones (GC) are potent immunosuppressors, which interfere with the immune system function both by promoting killing of white blood cells, and by suppressing the production of numerous cytokines, chemokines and other mediators of inflammation. Not surprisingly, GCs have been used for decades to combat inflammatory, autoimmune and lymphoproliferative diseases. Our goals are to understand the molecular mechanisms, cofactors and targets of GCs and their role in inflammation, cell proliferation and immune response.
GC signal through the intracellular glucocortcoid receptor (GR), a ligand-dependent transcription factor of the nuclear receptor family. Upon exposure to hormone, GR translocates to the nucleus, binds to GC response elements (GREs) on DNA and activates or represses a wide variety of genes. In addition to binding DNA directly, GR can ‘tether’ to other DNA-bound transcription factors by protein:protein interactions, typically repressing their activities. GR-dependent repression of AP-1 and NF-kB, for example, accounts for many immunosuppressive effects of GC yet, the molecular mechanisms of repression are not well understood. Furthermore, the broad actions of GC on the immune system likely involve additional players and mechanisms, but their identity is unknown.
We found that GRIP1, a member of the p160 family of nuclear receptor coactivators, served as a GR ligand-dependent corepressor at the AP-1 and NF-kB sites. This activity was mediated by a unique GRIP1 corepression domain (RD), which does not resemble any known protein. In a screen for RD-interacting factors, we isolated Interferon Regulatory Factor (IRF)-3, an essential component of the innate immune system responsible for the production a number of immunostimulatory cytokines, most notably type I interferon (IFN) in macrophages. GRIP1 functioned as an IRF3 coactivator contributing to IFN production. Unexpectedly, the IFN-Jak/STAT signaling pathway responsible for IFN-induced gene expression also relied on GRIP1. Interestingly, both IFN transcription and signaling were strongly attenuated by GC and GRIP1 sequestration by the activated GR mediated this immunosuppressive activity. Our current studies investigate the mechanisms promoting selective GRIP1 utilization in one pathway over another, its exact molecular function in each and the GRIP1 role in vivo.
Another factor isolated in the screen was a novel inhibitory histone methyltransferase (HMTase) Suv4-20, which specifically tri-methylates histone H4 lysine 20 facilitating the establishment and maintenance of constitutive heterochromatin associated with transcriptionally silent domains. Unexpectedly, we found that Suv4-20 actively participates in hormone-dependent transcriptional regulation as a GRIP1-associated cofactor for a subset of GR target genes including known suppressors of inflammatory response. Current projects are focusing on the mechanisms of Suv4-20 action on GR target genes and broadly on the mammalian transcriptome.
We use biochemical, molecular, cell-based and in vivo approaches to identify points of cross-talk between the GC and the pathways mediating inflammation, autoimmunity and uncontrolled cell proliferation. Understanding the major players and mechanisms of such interactions is essential for developing more specific therapies.
Caspary Research Building
541 East 71st Street
New York, NY 10021
Tel: 212.606.1462
Fax: 212.774.2560
©2008 Hospital for Special Surgery. 535 East 70th Street, New York, NY 10021